WT1 TCR-transduced T-cell therapy - Takara Bio

Drug Profile

WT1 TCR-transduced T-cell therapy - Takara Bio

Alternative Names: WT1 antigen-specific RetroNectin TCR gene therapy - Takara Bio; WT1 antigen-specific TCR-gene-transduced autologous lymphocytes - Takara Bio

Latest Information Update: 18 Nov 2016

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Mie University; Takara Bio
  • Class T lymphocyte cell therapies
  • Mechanism of Action Gene transference; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 01 Nov 2016 Takara Bio completes a phase I trial in Acute Myeloid leukaemia and myelodysplastic syndromes (second line therapy or greater) in Japan (SC) (UMIN000011519)
  • 07 May 2015 Mie University plans a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Second-line therapy or greater) in Japan (SC) (UMIN000017431)
  • 09 Apr 2014 Phase-I clinical trials in Acute myeloid leukaemia (second line therapy or greater) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top